MX2021013211A - Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1. - Google Patents

Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.

Info

Publication number
MX2021013211A
MX2021013211A MX2021013211A MX2021013211A MX2021013211A MX 2021013211 A MX2021013211 A MX 2021013211A MX 2021013211 A MX2021013211 A MX 2021013211A MX 2021013211 A MX2021013211 A MX 2021013211A MX 2021013211 A MX2021013211 A MX 2021013211A
Authority
MX
Mexico
Prior art keywords
compound
structural formula
preparation
xpo1 inhibitors
xpo1
Prior art date
Application number
MX2021013211A
Other languages
English (en)
Spanish (es)
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MX2021013211A publication Critical patent/MX2021013211A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021013211A 2019-05-01 2020-05-01 Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1. MX2021013211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841649P 2019-05-01 2019-05-01
PCT/US2020/031124 WO2020223678A1 (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Publications (1)

Publication Number Publication Date
MX2021013211A true MX2021013211A (es) 2022-03-11

Family

ID=70802955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013211A MX2021013211A (es) 2019-05-01 2020-05-01 Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.

Country Status (14)

Country Link
US (1) US12479806B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962898A1 (cg-RX-API-DMAC7.html)
JP (2) JP7630444B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004142A (cg-RX-API-DMAC7.html)
CN (1) CN114040909B (cg-RX-API-DMAC7.html)
AU (1) AU2020266170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021706A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135712A1 (cg-RX-API-DMAC7.html)
CR (1) CR20210590A (cg-RX-API-DMAC7.html)
IL (1) IL287673B1 (cg-RX-API-DMAC7.html)
MA (1) MA55808A (cg-RX-API-DMAC7.html)
MX (1) MX2021013211A (cg-RX-API-DMAC7.html)
SG (1) SG11202111993SA (cg-RX-API-DMAC7.html)
WO (1) WO2020223678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法
JP2021048976A (ja) * 2019-09-24 2021-04-01 株式会社ユニバーサルエンターテインメント 遊技機
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法

Also Published As

Publication number Publication date
AU2020266170A1 (en) 2021-11-25
US20220242832A1 (en) 2022-08-04
CR20210590A (es) 2022-03-11
JP2025072490A (ja) 2025-05-09
JP2022531576A (ja) 2022-07-07
JP7850834B2 (ja) 2026-04-23
CA3135712A1 (en) 2020-11-05
WO2020223678A1 (en) 2020-11-05
US12479806B2 (en) 2025-11-25
SG11202111993SA (en) 2021-11-29
IL287673B1 (en) 2026-01-01
EP3962898A1 (en) 2022-03-09
MA55808A (fr) 2022-03-09
JP7630444B2 (ja) 2025-02-17
CN114040909A (zh) 2022-02-11
IL287673A (en) 2021-12-01
BR112021021706A2 (pt) 2022-04-19
KR20220004142A (ko) 2022-01-11
AU2020266170B2 (en) 2026-02-26
CN114040909B (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
MX2021013211A (es) Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
CL2023003137A1 (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
AR120457A1 (es) Síntesis mejorada del compuesto inhibidor de g12c de kras
ECSP088368A (es) Derivados de 3-alquil-5-(4-alquil-5-oxo-tetrahidrofuran-2-il)-pirrolidin-2-ona como intermediarios en la síntesis de inhibidores de renina
CU23754B7 (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato.
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
UY39801A (es) Un proceso novedoso para la preparación de diamidas antranílicas
AR061310A1 (es) Procesos para preparar compuestos intermediarios utiles para la preparacion de cinacalcet
AR116423A1 (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino
ES2722854A1 (es) Procedimiento para preparar n-((1r,2s,5s)-2-((2-((5-cloropiridin-2-il)amino)-2-oxoacetil)amino)-5-(dimetilcarbamoil) ciclohexil)carbamato de terc-butilo
BR112022026981A2 (pt) Processos para a preparação de um composto e processo para a síntese de um composto
CL2020003015A1 (es) Conversión a escala preparativa de goniautoxinas en neosaxitoxina
CO5720995A2 (es) Compuesto novedoso
PE20110163A1 (es) Proceso para la preparacion de derivados de pirimidina sustituidos
PE20081497A1 (es) Nuevo procedimiento para la preparacion de 4-4'-(1-metil-1,2-etandiil)-bis-(2,6-piperazindiona)
ECSP088319A (es) Síntesis de inhibidores de renina que involucra una reacción de cicloadición
AR071005A1 (es) Preparacion selectiva de pirimidinas sustituidas
CL2023001018A1 (es) Compuestos inhibidores de autotaxina
CL2012000739A1 (es) Procedimientos de preparacion del acido 2-[(3,5-difluoro-3'-metoxi-1,1'-bifenil-4-il)amino]nicotinico; y uno de los compuestos intermedios considerados.
AR069759A1 (es) Proceso de intermediarios utiles en la preparacion de 5-(etil- dihidro-1-h-inden-2-il) 1h- imidazola
CO2021015370A2 (es) Proceso de preparación de compuestos de estrobilurina activos como fungicidas e intermedios de los mismos
MX2024015016A (es) Proceso para la preparacion de derivados de eter, tioeter o amina secundaria en la presencia de un catalizador acido heterogeneo
ES2568927T3 (es) Proceso para fabricar derivados de adamantano con alto rendimiento
MX2012008152A (es) Proceso para preparar voriconazol utilizando nuevos intermediarios.
AR125193A1 (es) Proceso para preparar compuestos fenólicos sustituidos con cicloalquilo